Benchmark maintains a 'Hold' rating on Myriad Genetics (Nasdaq: MYGN), raises price target from $25 to $30.

Benchmark analyst says ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE